BioCentury
ARTICLE | Company News

Genentech, Adaptive Biotechnologies to develop cancer T cell therapies

January 11, 2019 5:01 PM UTC

Adaptive Biotechnologies Corp. (Seattle, Wash.) and Genentech Inc. partnered to develop personalized and off-the-shelf T cell therapies for a broad range of cancers using Adaptive's TruTCR discovery and immune profiling platform. TruTCR combines immunosequencing, cellular immunology and computational biology to identify patient TCRs.

Adaptive will receive $300 million up front and is eligible for more than $2 billion in development, regulatory and commercial milestones, plus royalties...